IgAN Patient Support Group

The IgAN Patients support group formed in March 2014 as an informal support and information network. The group disseminates information about events, research and possible treatment for IgAN.

Current Projects :

The patient group has worked with Professor John Feehally to get IgAN recognised as a rare disease and accepted onto the rare diseases register

The group raises awareness about research in IgA Nephropathy and how patients can get involved as participants and advisors, such as SIGN – A trial of fostamatinib in IgA nephropathy, sponsored by Rigel Pharmaceuticals

The group keeps members up to date about relevant patient trials e.g. SC Trial which is testing the drug Blisimibod

The group works with Kidney Research UK to share information about IgAN

IgA Nephropathy Patient information Day

The next IgA Nephropathy Patient Information Day will take place at The Wellcome Institute, London on Saturday 24 November 2018, between 10am and 4pm. The event is open to all IgA nephropathy patients and carers.

The aim of this event is to learn more about the condition, share experiences and findout about the exciting research which will help us understand how IgA nephropathy.

Contact the group

4th IgA Nephropathy Patient information DayThe next IgA Nephropathy Patient Information Day will take place at the University of Leicester on Saturday 7th October 2017, between 10am and 3.30pm.The aim of this event is to inform patients, and their families, about the exciting research which will help us understand how IgA nephropathy develops. The day will include:• An introduction to IgA nephropathy (IgAN).• An overview of the scientific research which is helping us to get a clearer picture of the causes of IgAN. • Information about IgAN clinical trials• A tour around the new Mayer IgAN Research Labs based at the University of Leicester• The opportunity to speak to other IgAN patients and their families about their experience of the condition. If you would like to attend the event, register today.